Compare APP & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APP | BSX |
|---|---|---|
| Founded | 2012 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.6B | 137.8B |
| IPO Year | 2021 | 2010 |
| Metric | APP | BSX |
|---|---|---|
| Price | $458.69 | $69.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 20 |
| Target Price | ★ $703.71 | $108.75 |
| AVG Volume (30 Days) | 5.4M | ★ 11.3M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 115.23 | 55.20 |
| EPS | ★ 9.75 | 1.94 |
| Revenue | $5,480,717,000.00 | ★ $9,076,000,000.00 |
| Revenue This Year | $47.55 | $12.04 |
| Revenue Next Year | $29.08 | $10.48 |
| P/E Ratio | $46.10 | ★ $35.33 |
| Revenue Growth | ★ 16.38 | 12.49 |
| 52 Week Low | $200.50 | $67.56 |
| 52 Week High | $745.61 | $109.50 |
| Indicator | APP | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 47.99 | 30.45 |
| Support Level | $345.95 | N/A |
| Resistance Level | $473.69 | $76.77 |
| Average True Range (ATR) | 25.69 | 1.87 |
| MACD | 7.04 | 0.06 |
| Stochastic Oscillator | 56.98 | 17.55 |
AppLovin is a vertically integrated advertising technology company that acts as a demand-side platform for advertisers, a supply-side platform for publishers, and an exchange facilitating transactions between the two. About 80% of AppLovin's revenue comes from the DSP, AppDiscovery, while the remainder comes from the SSP, Max. AppLovin's primary tool for future growth is AXON 2, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.